Immunological Landscape of HER-2 Positive Breast Cancer.
Santiago MoragonCristina HernandoMaria Teresa Martinez-MartinezMarta TapiaBelen Ortega-MorilloAna LluchBegoña BermejoJuan Miguel CejalvoPublished in: Cancers (2022)
Understanding the biological aspects of immune response in HER2+ breast cancer is crucial to implementing new treatment strategies in these patients. It is well known that anti-HER2 therapy has improved survival in this population, yet a substantial percentage may relapse, creating a need within the scientific community to uncover resistance mechanisms and determine how to overcome them. This systematic review indicates the immunological mechanisms through which trastuzumab and other agents target cancer cells, also outlining the main trials studying immune checkpoint blockade. Finally, we report on anti-HER2 vaccines and include a figure exemplifying their mechanisms of action.
Keyphrases
- systematic review
- positive breast cancer
- immune response
- end stage renal disease
- ejection fraction
- newly diagnosed
- healthcare
- mental health
- meta analyses
- peritoneal dialysis
- free survival
- prognostic factors
- stem cells
- randomized controlled trial
- quality improvement
- mesenchymal stem cells
- toll like receptor
- bone marrow
- inflammatory response
- cell therapy